These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25632348)

  • 1. A time-indexed reference standard of adverse drug reactions.
    Harpaz R; Odgers D; Gaskin G; DuMouchel W; Winnenburg R; Bodenreider O; Ripple A; Szarfman A; Sorbello A; Horvitz E; White RW; Shah NH
    Sci Data; 2014 Nov; 1():140043. PubMed ID: 25632348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistency in the safety labeling of bioequivalent medications.
    Duke J; Friedlin J; Li X
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
    Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
    J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward multimodal signal detection of adverse drug reactions.
    Harpaz R; DuMouchel W; Schuemie M; Bodenreider O; Friedman C; Horvitz E; Ripple A; Sorbello A; White RW; Winnenburg R; Shah NH
    J Biomed Inform; 2017 Dec; 76():41-49. PubMed ID: 29081385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of new black box warnings and withdrawals for prescription medications.
    Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
    JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
    Szarfman A; Machado SG; O'Neill RT
    Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions.
    Hauben M; Horn S; Reich L
    Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reference set of clinically relevant adverse drug-drug interactions.
    Kontsioti E; Maskell S; Dutta B; Pirmohamed M
    Sci Data; 2022 Mar; 9(1):72. PubMed ID: 35246559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.
    Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J
    Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling".
    Cheng C; Guglielmo BJ
    Arch Intern Med; 2011 May; 171(10):946-7. PubMed ID: 21606102
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
    Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
    J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions.
    Hashiguchi M; Imai S; Uehara K; Maruyama J; Shimizu M; Mochizuki M
    PLoS One; 2015; 10(12):e0144263. PubMed ID: 26641634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IOM: overhaul drug safety monitoring.
    Kuehn BM
    JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
    [No Abstract]   [Full Text] [Related]  

  • 18. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
    Moore TJ; Furberg CD; Mattison DR; Cohen MR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

  • 20. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
    Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.